论文部分内容阅读
为明确对化疗耐药的早期预报是否可能,作者在1985年4月至1986年7月对随机选择的42例AML成人患者进行了前瞻性研究。全部患者骨髓中的原始细胞在诊断时均>50%。按FAB分型,M_1 6例,M_210例,M_3 5例,M_4 6例,M_5 11例,M_6 3例,另1例为原巨核细胞白血病。中位年龄为44岁(范围:18—68岁)。全部患者均接受相同的诱导化疗方案:柔红霉素70mg/m~2/d,I.V,第1—3天,阿糖胞苷200mg/m~2/d I.V,第1—7天,每11小时注1次。6-硫鸟嘌呤200mg/m~2/d,口服,第1—7天,每12小时服1次。化疗期内每天作血细胞计数。化疗第4天抽取
To determine whether early prediction of chemotherapy resistance was possible, the authors conducted a prospective study of 42 randomly selected AML adult patients from April 1985 to July 1986. The progenitor cells in the bone marrow of all patients were >50% diagnosed. According to the FAB classification, there were 6 patients with M_1, M_210 patients, 5 M_3 patients, 6 M_4 patients, 11 M_5 patients, 3 M_6 patients, and 1 patient with original megakaryocytic leukemia. The median age was 44 years (range: 18-68 years). All patients received the same induction chemotherapy regimen: daunorubicin 70 mg/m~2/d, IV, 1-3 days, cytarabine 200 mg/m~2/d IV, 1 to 7 days, each 11 hours note 1 time. 6-thioguanine 200mg/m~2/d, orally, on the 1st to 7th days, once every 12 hours. Blood cell counts were performed daily during the chemotherapy period. On the fourth day of chemotherapy